Literature DB >> 10339575

Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3.

C Coeshott1, C Ohnemus, A Pilyavskaya, S Ross, M Wieczorek, H Kroona, A H Leimer, J Cheronis.   

Abstract

Two important cytokines mediating inflammation are tumor necrosis factor alpha (TNFalpha) and IL-1beta, both of which require conversion to soluble forms by converting enzymes. The importance of TNFalpha-converting enzyme and IL-1beta-converting enzyme in the production of circulating TNFalpha and IL-1beta in response to systemic challenges has been demonstrated by the use of specific converting enzyme inhibitors. Many inflammatory responses, however, are not systemic but instead are localized. In these situations release and/or activation of cytokines may be different from that seen in response to a systemic stimulus, particularly because associations of various cell populations in these foci allows for the exposure of procytokines to the proteolytic enzymes produced by activated neutrophils, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (Cat G). To investigate the possibility of alternative processing of TNFalpha and/or IL-1beta by neutrophil-derived proteinases, immunoreactive TNFalpha and IL-1beta release from lipopolysaccharide-stimulated THP-1 cells was measured in the presence of activated human neutrophils. Under these conditions, TNFalpha and IL-1beta release was augmented 2- to 5-fold. In the presence of a specific inhibitor of NE and PR3, enhanced release of both cytokines was largely abolished; however, in the presence of a NE and Cat G selective inhibitor, secretory leucocyte proteinase inhibitor, reduction of the enhanced release was minimal. This finding suggested that the augmented release was attributable to PR3 but not NE nor Cat G. Use of purified enzymes confirmed this conclusion. These results indicate that there may be alternative pathways for the production of these two proinflammatory cytokines, particularly in the context of local inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10339575      PMCID: PMC26869          DOI: 10.1073/pnas.96.11.6261

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters.

Authors:  R C Kao; N G Wehner; K M Skubitz; B H Gray; J R Hoidal
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

2.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Authors:  A J Gearing; P Beckett; M Christodoulou; M Churchill; J Clements; A H Davidson; A H Drummond; W A Galloway; R Gilbert; J L Gordon
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

3.  An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes.

Authors:  A Antonelli-Orlidge; K B Saunders; S R Smith; P A D'Amore
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

4.  Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus.

Authors:  J M Molina; D T Scadden; R Byrn; C A Dinarello; J E Groopman
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

5.  Alpha-globulins suppress human leukocyte tumor necrosis factor secretion.

Authors:  P Scuderi; R T Dorr; J D Liddil; P R Finley; P Meltzer; A B Raitano; J Rybski
Journal:  Eur J Immunol       Date:  1989-05       Impact factor: 5.532

6.  Interaction of secretory leukocyte protease inhibitor with proteinase-3.

Authors:  N V Rao; B C Marshall; B H Gray; J R Hoidal
Journal:  Am J Respir Cell Mol Biol       Date:  1993-06       Impact factor: 6.914

7.  Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.

Authors:  G M McGeehan; J D Becherer; R C Bast; C M Boyer; B Champion; K M Connolly; J G Conway; P Furdon; S Karp; S Kidao
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

8.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.

Authors:  K M Mohler; P R Sleath; J N Fitzner; D P Cerretti; M Alderson; S S Kerwar; D S Torrance; C Otten-Evans; T Greenstreet; K Weerawarna
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

9.  Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3.

Authors:  M Padrines; M Wolf; A Walz; M Baggiolini
Journal:  FEBS Lett       Date:  1994-09-26       Impact factor: 4.124

10.  Purification and characterization of human recombinant precursor interleukin 1 beta.

Authors:  D Hazuda; R L Webb; P Simon; P Young
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

View more
  123 in total

Review 1.  Role of proteinase 3 in activation of endothelium.

Authors:  M E Taekema-Roelvink; C van Kooten; C A Verburgh; M R Daha
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Neutrophils in periodontal inflammation.

Authors:  David A Scott; Jennifer Krauss
Journal:  Front Oral Biol       Date:  2011-11-11

3.  Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor.

Authors:  M Kawasaki; K Kuwano; N Hagimoto; T Matsuba; R Kunitake; T Tanaka; T Maeyama; N Hara
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  Inflammasomes in cardiovascular diseases.

Authors:  Nisha Jain Garg
Journal:  Am J Cardiovasc Dis       Date:  2011-09-10

5.  Significant role of IL-1 signaling, but limited role of inflammasome activation, in oviduct pathology during Chlamydia muridarum genital infection.

Authors:  Uma M Nagarajan; James D Sikes; Laxmi Yeruva; Daniel Prantner
Journal:  J Immunol       Date:  2012-02-13       Impact factor: 5.422

6.  IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G.

Authors:  Emma Lefrançais; Stephane Roga; Violette Gautier; Anne Gonzalez-de-Peredo; Bernard Monsarrat; Jean-Philippe Girard; Corinne Cayrol
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 7.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

8.  Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity.

Authors:  Suyoung Bae; Taebong Kang; Jaewoo Hong; Siyoung Lee; Jida Choi; Hyunjhung Jhun; Areum Kwak; Kwangwon Hong; Eunsom Kim; Seunghyun Jo; Soohyun Kim
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

9.  IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation.

Authors:  B Siegmund; H A Lehr; G Fantuzzi; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

10.  Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3.

Authors:  L Armstrong; S I H Godinho; K M Uppington; H A Whittington; A B Millar
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.